A similar study suggested the use of mJX-594 (JX), a vaccinia virus equipped with GM-CSF (cytokine), as an approach to remodel the tumor microenvironment and augment sensitivity to αPD-1 and/or αCTLA-4 immunotherapy. The gene discussed is CSF2; the disease is neoplasm.